ArticleIJTLD open2026
A eureka moment - using coalface data for discovery on TB disease and financial relief.
Article in IJTLD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough Australia maintains a low incidence of TB, elimination remains elusive. To support program delivery and evaluation, intervention fidelity, trends and patterns in the provision of financial relief were explored. Insights for practitioners and funders inform decision-making.
methodsData and process mining approaches were used to explore the dispersal of vouchers and small grants processed through the Victorian Tuberculosis Program. Data sources identified, curated, and analysed included financial relief dispersal records and public health documentation (sociodemographic, TB, and health care access characteristics). Queries and analysis were shaped through practitioner consultation.
resultsOf 3,811 TB events, 15% received financial relief during treatment. Relief recipients were younger, more often male, and more likely to have pulmonary disease and cavitation. Twice as likely to be part of whole genome sequencing-defined transmission clusters, recipients also experienced more treatment interruptions. Practitioner insights revealed that financial relief functioned as a response to hardship and as an enabler or incentive to support engagement with care.
conclusionThe observed patterns and trends suggest an intersection between TB vulnerability and financial relief. Low-incidence, high-income settings likely benefit from financial relief to mitigate structural inequities. Further research should detail the nature of financial hardship, co-occurring indicators of TB, and their proximity to TB care outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.